,i #aagth ,,congress #ast ,session ,h4 ,r4 #cdi ,,in ,,the ,,house ,,of ,,representatives ,january #ai1 #bjba ,ms4 ,kuster 7for herself and ,mr4 ,jeffries7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to direct the ,secretary of ,health and ,human ,services to award contracts1 grants1 and cooperative agreements to expand and enhance capacity for manufacturing covered products to prevent and control the spread of ,,sars-,co,v-#b and ,,covid-#ai4 #a4 ,short title ,this ,act may be cited as the ,coronavirus ,vaccine and ,therapeutic ,development ,act of #bjba4 #b4 ,covered product development and procurement 7a7 ,enhancing development1 procurement1 and manufacturing capacity 7#a7 ,in general ,the ,secretary of ,health and ,human ,services shall1 as appropriate1 award contracts1 grants1 and cooperative agreements1 and enter into other transactions-- 7,a7 expanding and enhancing covered product research and development2 7,b7 procuring covered products2 and 7,c7 expanding and enhancing capacity for manufacturing covered products4 7#b7 ,authorization of appropriations ,to carry out this subsection1 there is authorized to be appropriated #bj1jjj1jjj1jjj for fiscal years #bjba through #bjbe1 to remain available until expended4 7b7 ,report on vaccine and therapeutic manufacturing and administration capacity ,not later than ,december #ca1 #bjba1 the ,secretary shall submit to the ,committee on ,energy and ,commerce of the ,house of ,representatives and the ,committee on ,health1 ,education1 ,labor and ,pensions of the ,senate a report detailing-- 7#a7 an assessment of the estimated supply of covered products necessary to prevent and control the spread of ,,sars-,co,v-#b and ,,covid-#ai1 domestically and internationally2 7#b7 an assessment of current and future domestic manufacturing capacity for covered products1 including identification of any gaps in manufacturing capacity1 including-- 7,a7 identification of any gaps in capacity for manufacturing2 and 7,b7 an analysis of the effects of shifting manufacturing resources to address ,,covid-#ai2 7#c7 activities conducted to expand and enhance manufacturing capacity for covered products to levels sufficient to prevent and control the spread of ,,sars-,co,v-#b and ,,covid-#ai1 domestically and internationally1 including a list and explanation of all contracts1 grants1 and cooperative agreements awarded1 and other transactions entered into1 for purposes of such expansion and enhancement and how such activities will help to meet future domestic manufacturing capacity needs2 7#d7 a plan for the ongoing support of enhanced manufacturing capacity for covered products1 domestically and internationally2 and 7#e7 a plan-- 7,a7 to ensure that manufacturing capacity meets the distribution targets and goals of covered products1 domestically and internationally2 and 7,b7 to support the administration of covered products approved or authorized by the ,food and ,drug ,administration to prevent and control the spread of ,,sars-,co,v-#b and ,,covid-#ai1 domestically and internationally1 including ,federal workforce enhancements necessary to administer such products4 7c7 ,definitions ,in this section3 7#a7 ,the term ancillary medical supply includes-- 7,a7 vials2 7,b7 bandages2 7,c7 alcohol swabs2 7,d7 syringes2 7,e7 needles2 7,f7 gloves and other personal protective equipment2 and 7,g7 other medical products the ,secretary determines necessary for the administration of covered products4 7#b7 ,the term covered product means a vaccine1 therapeutic1 or ancillary medical supply to prevent and control the spread of ,,sars-,co,v-#b and ,,covid-#ai4 7#c7 ,the term ,secretary means the ,secretary of ,health and ,human ,services4